|Day Low/High||102.99 / 103.36|
|52 Wk Low/High||69.59 / 104.78|
ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company with more than 4 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath.
ResMed (NYSE: RMD, ASX: RMD) today announced the hire of its first chief technology officer (CTO), Bobby Ghoshal, effective today.
ResMed (NYSE: RMD) today announced it will report its third quarter of fiscal year 2018 results on Thursday, April 26, 2018, after the New York Stock Exchange market closes.
The most recent short interest data has been released for the 01/12/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Providing more Purchasing Power for Providers at no Additional Cost.
Although equity index futures are lower, this whole thing has been taken in stride. For now.
A partial list of names that are showing signs of breaking out Monday.
The most recent short interest data has been released for the 11/15/2017 settlement date, which shows a 1,071,731 share decrease in total short interest for ResMed Inc. , to 6,966,017, a decrease of 13.33% since 10/31/2017.
Managing compliance for sleep apnea patients and increasing resupply revenue just got easier for home medical equipment (HME) providers, as Brightree today announced automated resupply enrollment for patients managed by...
The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 1,305,275 share decrease in total short interest for ResMed Inc. , to 10,131,531, a decrease of 11.41% since 04/13/2017.
Brightree®, the leading provider of cloud-based software for helping post-acute care companies improve business performance and patient outcomes, today announced that its home medical equipment (HME) billing and...
Jim Cramer names a few of his favorite things: housing, bank, material and tech stocks, oil, copper and deregulation.
Jim Cramer takes a closer look at ResMed and its future as a medical-device maker focusing on sleep apnea and COPD.
Short-sellers are feeling the pressure this year, but you don't have to if you take a look at these four stock that could face short squeezes.
The short trade is crowded in these four big stocks.
At CES 2017, SleepScore Labs shared exciting new information that will change the way people think about their sleep.
ResMed (RMD) reported earnings and revenue that fell short of analysts' expectations for the 2017 fiscal first quarter.
Cramer is concerned about Dave & Buster's but says Chipotle's problems are behind it.
When it comes to stock prices, competition has a lot of influence, Cramer says.
Today ResMed welcomed positive results from the independent Home Oxygen Therapy- Home Mechanical Ventilation (HOT-HMV) study 1 regarding the benefits of home non-invasive ventilation (NIV).
The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 1,147,291 share increase in total short interest for ResMed Inc. , to 12,554,278, an increase of 10.06% since 07/29/2016.
Jefferies reduced its rating on ResMed (RMD) stock to 'underperform' from 'hold' on Tuesday.
Here are Tuesday's top research calls, including an upgrade for Square and new coverage of Chipotle Mexican Grill, Darden Restaurants and McDonald's.
Trade-Ideas LLC identified ResMed (RMD) as a post-market laggard candidate
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.